Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer

Trial Identifier: D419QC00007
Sponsor: AstraZeneca
NCTID:: NCT04774380
Start Date: November 2021
Primary Completion Date: June 2023
Study Completion Date: March 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BG Burgas, BG, 8000
BG Gabrovo, BG, 5300
BG Panagyurishte, BG, 4500
BG Plovdiv, BG, 4000
BG Ruse, BG, 7002
BG Sofia, BG, 1407
BG Sofia, BG, 1330
BG Sofia, BG, 1303
CA Toronto, CA, M5G 2M9
CA, NS Halifax, NS, CA, B3H 1V7
CA, ON London, ON, CA, N6A 4L6
CA, ON Ottawa, ON, CA, K1H 8L6
CA, ON Sudbury, ON, CA, P3E 5J1
CA, QC Greenfield Park, QC, CA, J4V 2G9
CA, QC Montreal, QC, CA, H3T 1E2
CA, QC Montreal, QC, CA, H4A 3J1
CA, QC Quebec, QC, CA, G1V 4G5
CZ Brno, CZ, 656 53
CZ Brno, CZ, 625 00
CZ Burgas, CZ, 180 81
CZ Olomouc, CZ, 779 00
CZ Ostrava, CZ, 703 00
CZ Plzen - Bory, CZ, 305 99
CZ Praha 4, CZ, 14059
DE Berlin, DE, 13125
DE Berlin, DE, 12351
DE Gauting, DE, 82131
DE Hamburg, DE, 20251
DE Heidelberg, DE, 69126
DE Immenstadt, DE, 87509
DE Jena, DE, 07747
DE Kassel, DE, 34125
DE Köln, DE, 51109
IT Ancona, IT, 60126
IT Aviano, IT, 33081
IT Bari, IT, 70124
IT MELDOLA, IT, 47014
IT Milano, IT, 20141
IT Napoli, IT, 80131
IT Orbassano, IT, 10043
IT Palermo, IT, 90146
IT Pisa, IT, 56124
IT Roma, IT, 00168
TR Adana, TR, 01120
TR Adapazari, TR, 54290
TR Ankara, TR, 06010
TR Ankara, TR, 06100
TR Ankara, TR, 06800
TR Antalya, TR, 07070
TR Bursa, TR, 16059
TR Edirne, TR, 22030
TR Istanbul, TR, 34098
TR Istanbul, TR, 34722
TR Izmir, TR, 35100
TR Malatya, TR, 44280
TR Pamukkale, TR, 20070
TR Samsun, TR